BALAXI PHARMACEUTICALS peers

·UnclassifiedChart ›

Companies like BALAXI PHARMACEUTICALSlatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALAXI₹19.71

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹109 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
BALAXI
FY26
PAR
FY26
STEELCITY
FY26
LATTEYS
FY26
Peer
Average
Valuation — at last close
P/E75.81×11.33×◆ 8.15×29.98×16.49× +360%
P/B◆ 0.44×1.33×0.85×4.48×2.22× -80%
EV/EBITDA17.59×6.23×◆ 3.93×19.61×9.92× +77%
Market Cap₹109 Cr₹149 Cr₹118 Cr₹107 Cr₹124 Cr -13%
Growth
Revenue CAGR 3Y-7.05%2.68%◆ 4.48%—3.58% -297%
Revenue CAGR 5Y3.15%—◆ 3.53%—3.53% -11%
Net Income CAGR 3Y-68.64%4.97%◆ 8.43%—6.70% -1124%
Revenue YoY (latest Q)14.05%-4.28%28.51%◆ 59.21%27.81% -49%
Net Income YoY (latest Q)◆ 347.57%-36.36%66.71%182.25%70.87% +390%
Profitability
EBITDA Margin3.16%16.53%◆ 26.84%5.61%16.33% -81%
Net Income Margin0.52%12.65%◆ 22.95%3.04%12.88% -96%
Return on Common Equity0.59%12.43%10.80%◆ 16.11%13.11% -96%
Return on Capital Employed2.40%12.30%11.64%◆ 23.87%15.94% -85%
Return on Assets0.44%◆ 10.55%6.33%5.52%7.47% -94%
Credit & Quality
Total Debt/Equity0.22×◆ 0.00×0.07×0.91×0.33× -33%
Interest Coverage1.63×◆ 105.48×17.51×4.78×42.59× -96%
Scale — latest FY
Revenue / Total Income₹270 Cr₹104 Cr₹62.3 Cr₹117 Cr₹94.3 Cr +187%
Net Income₹1.4 Cr₹13.1 Cr₹14.3 Cr₹3.6 Cr₹10.3 Cr -86%
Total Assets₹337 Cr₹129 Cr₹237 Cr₹82.6 Cr₹150 Cr +125%
EPS₹0.26₹10.65₹9.57₹0.62₹6.95 -96%
Book Value per Share₹45.12₹91.01₹91.35₹4.15₹62.17 -27%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.